These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30790353)

  • 1. Epstein-Barr virus latent gene EBNA-1 genetic diversity among transplant patients compared with patients with infectious mononucleosis.
    Sullivan K; Isabel S; Khodai-Booran N; Paton TA; Abdulnoor M; Dipchand AI; Hébert D; Ng VL; Allen UD
    Clin Transplant; 2019 Apr; 33(4):e13504. PubMed ID: 30790353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in posttransplant lymphoproliferative disorders which have infrequent p53 mutations.
    Greiner TC; Abou-Elella AA; Smir BN; Orazi A; Hinrichs S; Anderson J; Gross T; Bierman P; Hauke R
    Leuk Lymphoma; 2000 Aug; 38(5-6):563-76. PubMed ID: 10953978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
    Riddler SA; Breinig MC; McKnight JL
    Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients.
    Heldman MR; Edlefsen KL; Pepper G; Kapnadak SG; Rakita RM; Fisher CE; Limaye AP
    Transpl Infect Dis; 2022 Dec; 24(6):e13933. PubMed ID: 36000190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic diversity of Epstein-Barr virus in the setting of transplantation relative to non-transplant settings: A feasibility study.
    Allen UD; Hu P; Pereira SL; Robinson JL; Paton TA; Beyene J; Khodai-Booran N; Dipchand A; Hébert D; Ng V; Nalpathamkalam T; Read S
    Pediatr Transplant; 2016 Feb; 20(1):124-9. PubMed ID: 26578436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
    Kinch A; Sundström C; Tufveson G; Glimelius I
    Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder.
    Maloney EM; Busque VA; Hui ST; Toh J; Fernandez-Vina M; Krams SM; Esquivel CO; Martinez OM
    JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32213705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of EBNA-1 and LMP-1 variants in diseases associated with EBV infection in Chinese children.
    Ai J; Xie Z; Liu C; Huang Z; Xu J
    Virol J; 2012 Jan; 9():13. PubMed ID: 22236445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
    Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
    Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell specific internal translation efficiency of Epstein-Barr virus present in solid organ transplant patients.
    Isaksson A; Berggren M; Ekeland-Sjöberg K; Samuelsson T; Ricksten A
    J Med Virol; 2007 May; 79(5):573-81. PubMed ID: 17385682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus nuclear antigen-2 detection and typing in immunocompromised children correlated with lymphoproliferative disorder biopsy findings.
    Mendes TM; Oliveira LC; Yamamoto L; Del Negro GM; Okay TS
    Braz J Infect Dis; 2008 Jun; 12(3):186-91. PubMed ID: 18833401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus DNAemia in Iranian liver transplant recipients and assessment of its variation in posttransplant lymphproliferative disorder patients by quantitative polymerase chain reaction assay.
    Jamalidoust M; Geramizadeh B; Pouladfar G; Namayandeh M; Asaie S; Aliabadi N; Nikeghbalian S; Ziyaeyan M
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():306-11. PubMed ID: 25894179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
    Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of PCR results in the diagnosis of Epstein-Barr virus infections].
    Karadağ Geçgel S; Ersoy A; Sevinir BB; Sınırtaş M; Göral G
    Mikrobiyol Bul; 2012 Oct; 46(4):594-606. PubMed ID: 23188573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys.
    Schmidtko J; Wang R; Wu CL; Mauiyyedi S; Harris NL; Della Pelle P; Brousaides N; Zagachin L; Ferry JA; Wang F; Kawai T; Sachs DH; Cosimi BA; Colvin RB
    Transplantation; 2002 May; 73(9):1431-9. PubMed ID: 12023621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBNA-1 sequence variations reflect active EBV replication and disease status or quiescent latency in lymphocytes.
    Wang JT; Sheeng TS; Su IJ; Chen JY; Chen MR
    J Med Virol; 2003 Mar; 69(3):417-25. PubMed ID: 12526054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases.
    Haque T; Chaggar T; Schafers J; Atkinson C; McAulay KA; Crawford DH
    J Med Virol; 2011 Feb; 83(2):311-6. PubMed ID: 21181928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and virologic outcomes in high-risk adult Epstein-Barr virus mismatched organ transplant recipients.
    Kumar D; Patil N; Husain S; Chaparro C; Bhat M; Kim SJ; Humar A
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28489256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.